Spironolactone Suspension
Product Images NDC 17856-1233

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 17856-1233). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (17856 1233 01 Rev.1 Case Label)

1 (17856 1233 01 Rev.1 Case Label)
Label for SPIRONOLACTONE oral suspension USP, delivering 5 mg/mL concentration, packaged by Unit Dose Solutions and distributed by Atlantic Biologicals Corp. The label includes storage instructions and a quantity of 110 ENFit syringes. The label also displays a barcode, QR code, serial number, and reorder phone number.*
FDA Label Image

2 (17856 1233 02 Rev.1 Case Label)

2 (17856 1233 02 Rev.1 Case Label)
Label for Spironolactone oral suspension, USP, strength 12.5 mg per 2.5 mL, provided by Atlantic Biologicals Corp. The label indicates storage instructions, dosing of 12.5 mg/2.5 mL, and packaging in 45 units per syringe. Additional details include manufacturer and distributor information, a barcode, and reorder contact number.*
FDA Label Image

3 (17856 1233 03 Rev.1 Case Label)

3 (17856 1233 03 Rev.1 Case Label)
SPIRONOLACTONE oral suspension label showing 15 mg/3 mL strength, packaged in an ENFit syringe with a quantity of 110. Label includes storage instructions for 20°-25°C with permitted excursions, a barcode, serial number, expiration, GTIN, and lot fields, and manufacturer details listing Atlantic Biologicals Corp. and Unit Dose Services, LLC.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of the active ingredient spironolactone. The diagram shows the molecular arrangement including rings and functional groups characteristic of spironolactone.*
FDA Label Image

Figure 1. Survival By Treatment Group In Rales (Figure 01)

Figure 1. Survival By Treatment Group In Rales (Figure 01)
A Kaplan-Meier survival plot comparing the probability over months between spironolactone and placebo groups. The graph shows two lines, with spironolactone group having 822 subjects and placebo group 841 subjects. The x-axis represents time in months, and the y-axis represents probability. A log-rank p-value of less than 0.001 is indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.